Seattle Genetics Secures $9,000,000 New Financing Round

Feed Type
Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=69d78788-f8d5-4a75-92a6-97c22951b654
Date
1/21/2014
Company Name
Seattle Genetics
Mailing Address
21823 30th Drive S.E Bothell, WA 98021
Company Description
Seattle Genetics is a biotechnology company focused on developing and commercializing innovative, empowered antibody-based therapies for the treatment of cancer. We are the industry leader in antibody-drug conjugates (ADCs), a technology designed to harness the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells.
Website
http://www.seattlegenetics.com
Transaction Type
Venture Equity
Transaction Amount
$9,000,000
Transaction Round
Undisclosed
Proceeds Purposes
Seattle Genetics and Takeda are jointly developing Adcetris, which has been approved in 39 countries.
M&A Terms
Venture Investor
Takeda Ventures